1. Teva Pharmaceutical Industries named Kare Schultz as CEO. Schultz was previously CEO at Lundbeck. (Reuters)
2. Allergan paid the Saint Regis Mohawk Tribe, a sovereign tribal nation in upstate New York, $13.75 million as part of a plan to dismiss patent challenges for its eye-drug Restasis. Allergan has transferred the patents to the tribe, which will claim sovereign immunity to dismiss patent challenges and then license the patent back to Allergan. (NYT)
3. Google has invested in oncology for the first time. Its VC arm Google Ventures participated in a $93 million fundraising round for Gritstone Oncology, which is developing cancer vaccines. (Business Insider)
4. Johnson & Johnson ended its program to develop a drug for hepatitis C. The drugmaker said it will shift resources into hepatitis B. (Endpoints News)
5. AbbVie reported the death of two patients in a Phase-III trial for experimental rheumatoid arthritis drug upadacitinib. (Reuters)
